Since the αvβ3 and αvβ5 integrin inhibitor, SB273005, showed the most promising subtype-specific effect by targeting exclusively the mesenchymal-like cell lines, we investigated the impact of ITGAV on BLCA patient survival. The gene discussed is ITGAV; the disease is bladder transitional cell carcinoma.